Plus Therapeutics (PSTV) director receives new option and RSU grants

Rhea-AI Filing Summary

PLUS THERAPEUTICS, INC. director Howard Clowes reported new equity-based compensation awards. He received a stock option covering 3,686 shares of common stock at an exercise price of $5.76 per share, expiring on May 14, 2036. These options vest in substantially equal monthly installments over 12 months and vest in full at the company’s 2027 annual stockholder meeting if he continues serving through each vesting date.

Clowes was also granted 3,686 Restricted Stock Units, each representing a contingent right to receive one share of common stock. The RSUs vest in four substantially equal quarterly installments, with one-quarter vesting on July 1, 2026 and the remainder vesting quarterly thereafter, subject to continued service. These are non-cash, compensation-related acquisitions rather than open-market share purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Clowes Howard

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	3,686	$0.00	--
Grant/Award	Stock Option (Right to Buy)	3,686	$0.00	--

Holdings After Transaction: Restricted Stock Units — 3,686 shares (Direct, null); Stock Option (Right to Buy) — 3,686 shares (Direct, null)

Footnotes (1)

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments, commencing with 1/4th vesting on July 1, 2026 and the remainder vesting quarterly thereafter. The options vest monthly over 12 months from the grant date in substantially equal monthly increments, provided that the options vest in full on the Issuer's 2027 Annual Stockholder Meeting, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting.

Key Figures

Option grant size: 3,686 shares Option exercise price: $5.76 per share Option expiration: May 14, 2036 +2 more

5 metrics

Option grant size 3,686 shares Stock Option (Right to Buy) granted to director

Option exercise price $5.76 per share Exercise price for stock options granted May 14, 2026

Option expiration May 14, 2036 Expiration date of director stock options

RSU grant size 3,686 units Restricted Stock Units awarded to director

RSU initial vest date July 1, 2026 First 1/4 of RSUs vest on this date

Key Terms

Restricted Stock Units, contingent right, vest ratably, exercise price, +1 more

5 terms

Restricted Stock Units financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"represents a contingent right to receive one share of the Issuer's Common Stock"

vest ratably financial

"The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments"

exercise price financial

"conversion_or_exercise_price": "5.7600""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date": "2036-05-14T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Clowes Howard

(Last) (First) (Middle)

C/O PLUS THERAPEUTICS INC.

6420 LEVIT GREEN BOULEVARD, SUITE 310

(Street)

HOUSTON TEXAS 77021

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(1)	05/14/2026		A		3,686		(1)	(1)	Common Stock	3,686	$0	3,686	D
Stock Option (Right to Buy)	$5.76	05/14/2026		A		3,686		(2)	05/14/2036	Common Stock	3,686	$0	3,686	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs awarded vest ratably over four quarters in substantially equal 1/4th increments, commencing with 1/4th vesting on July 1, 2026 and the remainder vesting quarterly thereafter.

2. The options vest monthly over 12 months from the grant date in substantially equal monthly increments, provided that the options vest in full on the Issuer's 2027 Annual Stockholder Meeting, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting.

	Andrew Sims, as attorney-in-fact	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did PLUS THERAPEUTICS (PSTV) grant to director Howard Clowes?

PLUS THERAPEUTICS granted director Howard Clowes stock options and Restricted Stock Units, each covering 3,686 shares of common stock. The awards are part of his equity compensation and are structured with multi-year vesting schedules tied to continued board service.

How do the new stock options for PLUS THERAPEUTICS (PSTV) director vest?

The stock options for 3,686 shares vest in substantially equal monthly installments over 12 months. They also vest in full at the 2027 annual stockholder meeting if Howard Clowes continues serving the company through each applicable vesting date.

What is the exercise price and expiration date of the PLUS THERAPEUTICS (PSTV) options?

The stock options granted to Howard Clowes have an exercise price of $5.76 per share and expire on May 14, 2036. These terms define the cost to purchase shares and the final date the options can be exercised.

How do the Restricted Stock Units for PLUS THERAPEUTICS (PSTV) director vest?

The 3,686 Restricted Stock Units vest ratably over four quarters in substantially equal one-quarter increments. Vesting starts with one-quarter on July 1, 2026, with the remaining three quarters vesting quarterly thereafter, contingent on continued service.

Are the PLUS THERAPEUTICS (PSTV) Form 4 transactions open-market buys or sells?

No. The Form 4 shows compensation-related grants: stock options and Restricted Stock Units awarded to director Howard Clowes. These are non-cash equity awards, not open-market purchases or sales of PLUS THERAPEUTICS common stock.

What does each RSU granted to the PLUS THERAPEUTICS (PSTV) director represent?

Each Restricted Stock Unit represents a contingent right to receive one share of PLUS THERAPEUTICS common stock. Actual share delivery depends on satisfaction of the vesting schedule, including quarterly vesting dates beginning July 1, 2026, and continued service conditions.